Patient demographics, disease characteristics and treatment history at registration
| Characteristic . | Arm 1 POM-DEX (n = 39) . | Arm 2 IXA-POM-DEX (n = 38) . |
|---|---|---|
| Median age at registration (range) | 64 (52-85) | 66 (41-83) |
| Age at registration (y) | ||
| 40-64 | 20 (51.3%) | 14 (36.8%) |
| 65-74 | 8 (20.5%) | 18 (47.4%) |
| 75-85 | 11 (28.2%) | 6 (15.8%) |
| Male | 23 (59.0%) | 19 (50.0%) |
| Race | ||
| White | 32 (82.1%) | 30 (79.0%) |
| Black | 5 (12.8%) | 6 (15.8%) |
| Asian | 0 | 1 (2.6%) |
| Not reported | 2 (5.1%) | 1 (2.6%) |
| Hispanic or Latino | 2 (5.1%) | 1 (2.6%) |
| ECOG performance score | ||
| 0 | 15 (38.5%) | 13 (34.2%) |
| 1 | 21 (53.9%) | 24 (63.2%) |
| 2 | 3 (7.7%) | 1 (2.6%) |
| Time from diagnosis to study entry | ||
| <2 y | 5 (12.8%) | 6 (15.8%) |
| 2.0-4.9 y | 18 (46.2%) | 20 (52.6%) |
| ≥5.0 y | 16 (46.0%) | 13 (31.6%) |
| ISS stage at initial diagnosis | ||
| 1 | 9 (23.1%) | 15 (39.5%) |
| 2 | 14 (35.9%) | 12 (31.6%) |
| 3 | 6 (15.4%) | 2 (5.3%) |
| Unknown | 10 (25.6%) | 9 (23.7%) |
| High-risk cytogenetics∗ | 15 (38.5%) | 19 (50.0%) |
| Pevious ASCT | 12 (30.8%) | 20 (52.6%) |
| Previous proteasome inhibitor | 37 (94.9%) | 35 (92.1%) |
| Previous daratumumab-containing regimen | 0 (0.0%) | 0 (0.0%) |
| LEN refractory yes, progression during treatment | 35 (89.7%) | 34 (89.5%) |
| If yes, progression within 60 d of last dose | 4 (10.3%) | 4 (10.5%) |
| Characteristic . | Arm 1 POM-DEX (n = 39) . | Arm 2 IXA-POM-DEX (n = 38) . |
|---|---|---|
| Median age at registration (range) | 64 (52-85) | 66 (41-83) |
| Age at registration (y) | ||
| 40-64 | 20 (51.3%) | 14 (36.8%) |
| 65-74 | 8 (20.5%) | 18 (47.4%) |
| 75-85 | 11 (28.2%) | 6 (15.8%) |
| Male | 23 (59.0%) | 19 (50.0%) |
| Race | ||
| White | 32 (82.1%) | 30 (79.0%) |
| Black | 5 (12.8%) | 6 (15.8%) |
| Asian | 0 | 1 (2.6%) |
| Not reported | 2 (5.1%) | 1 (2.6%) |
| Hispanic or Latino | 2 (5.1%) | 1 (2.6%) |
| ECOG performance score | ||
| 0 | 15 (38.5%) | 13 (34.2%) |
| 1 | 21 (53.9%) | 24 (63.2%) |
| 2 | 3 (7.7%) | 1 (2.6%) |
| Time from diagnosis to study entry | ||
| <2 y | 5 (12.8%) | 6 (15.8%) |
| 2.0-4.9 y | 18 (46.2%) | 20 (52.6%) |
| ≥5.0 y | 16 (46.0%) | 13 (31.6%) |
| ISS stage at initial diagnosis | ||
| 1 | 9 (23.1%) | 15 (39.5%) |
| 2 | 14 (35.9%) | 12 (31.6%) |
| 3 | 6 (15.4%) | 2 (5.3%) |
| Unknown | 10 (25.6%) | 9 (23.7%) |
| High-risk cytogenetics∗ | 15 (38.5%) | 19 (50.0%) |
| Pevious ASCT | 12 (30.8%) | 20 (52.6%) |
| Previous proteasome inhibitor | 37 (94.9%) | 35 (92.1%) |
| Previous daratumumab-containing regimen | 0 (0.0%) | 0 (0.0%) |
| LEN refractory yes, progression during treatment | 35 (89.7%) | 34 (89.5%) |
| If yes, progression within 60 d of last dose | 4 (10.3%) | 4 (10.5%) |
ECOG, Eastern Cooperative Oncology Group.
High risk cytogenetics: defined as del(1p), gain of 1q, t(4;14) t(14;16), t(14;20), or del(17p).